Parenteral led the route of administration landscape in the acute myeloid leukemia treatment market in 2025, accounting for a 64.02% share. Its leadership is underpinned by the treatment realities of acute myeloid leukemia, where intensive therapies, induction regimens, and closely monitored administration remain central to patient management. Parenteral delivery fits established hospital-based care pathways, supports precise dosing in clinically fragile patients, and aligns with the need for direct supervision during complex treatment phases, which continues to anchor its dominant share in the market.

Oral is the fastest-growing route of administration in the acute myeloid leukemia treatment market as treatment approaches increasingly favor settings and regimens that reduce administration burden while extending therapeutic continuity beyond infusion-centered care. Its momentum is reinforced through the practical advantage of easier long-term use, especially where ongoing treatment management benefits from greater patient convenience and less dependence on facility-based delivery. Compared with parenteral alternatives, oral therapies are experiencing stronger uptake because they better match the shift toward more flexible treatment pathways without removing the need for continued leukemia care.

End Use Segment Analysis: Hospitals and Clinics (Largest Segment) vs Homecare Setting (Fastest-Growing Segment)

Hospitals and Clinics held the dominant position in the acute myeloid leukemia treatment market in 2025 with a 55.13% share. This segment remains dominant because acute myeloid leukemia treatment often requires intensive diagnostic workups, supervised drug administration, management of complications, and continuous clinical monitoring that are most effectively delivered in institutional settings. The concentration of hematology expertise, supportive care infrastructure, and emergency response capability within hospitals and clinics continues to preserve their leading share across the market.

Homecare Setting is emerging as the fastest-growing end-use segment in the acute myeloid leukemia treatment market due to the rising need for treatment models that ease the burden of repeated facility visits while supporting ongoing care outside traditional institutions. Growth is being reinforced by the practical suitability of select therapies and follow-up routines for at-home management, particularly when patients require continuity of care rather than constant inpatient supervision. Relative to hospitals and clinics, homecare settings are gaining momentum because they align more closely with evolving care delivery preferences centered on accessibility and day-to-day treatment convenience.